Physician profile
John Sheehan
NPI 1225188337
$882.77
in general payments reported to CMS, 2019-2025
6 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $426 · 2020: $111 · 2022: $27.76 · 2024: $318.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Gift: $166 · Food and Beverage: $151.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Gift | $166.45 |
| Food and Beverage | $151.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nobel Biocare USA | $337.17 | 2019-2022 | |
| A-Dec, INC. | $166.45 | 2024 | |
| Dentsply Sirona INC | $151.14 | 2024 | Suresmile, Smartlite Focus |
| Align Technology, INC. | $124.00 | 2019 | |
| Carestream Dental, LLC | $94.99 | 2019 | |
| Biolase, INC. | $9.02 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Sheehan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.